Trial Profile

Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With High-Risk Genomic Features.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
Indications Chronic lymphocytic leukaemia; Pneumococcal infections
Focus Pharmacodynamics

12 Dec 2023 Long term results (N=49) evaluating the impact of Lenalidomide early treatment on chronic lymphocytic leukemia, complicating infections (INF), and second neoplasms (SN). presented at the 65th American Society of Hematology Annual Meeting and Exposition
19 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2024.
19 Jan 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com